SCHEMBL6257672

SCHEMBL6257672

COC(=O)C[C@H](Cc1ncc(-c2ccccc2)o1)NC(=O)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.46
CTRB1 P17538 2/20 0.46
TACR1 P25103 1/20 0.45
NPPA P01160 2/20 0.43
MME P08473 2/20 0.43
CASP1 P29466 1/20 0.43
ALDH1A1 P00352 1/20 0.43
ALOX15 P16050 1/20 0.43
FFAR1 O14842 1/20 0.42
ITGA4 P13612 1/20 0.42
ITGB7 P26010 1/20 0.42
CTSL P07711 2/20 0.41
CTSB P07858 2/20 0.41
CTSS P25774 2/20 0.41
CTSK P43235 2/20 0.41
REN P00797 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6254719 0.83 NPPA (0.52) ATMTACR1NPPAMMEFFAR1
SCHEMBL6508639 0.82 ATM (0.47) ATMTACR1NPPAMMEALDH1A1
SCHEMBL7280375 0.80 CTRB1 (0.68) ATMCTRB1TACR1ALDH1A1ALOX15
SCHEMBL28184491 0.80 CTRB1 (0.68) ATMCTRB1TACR1ALDH1A1ALOX15
SCHEMBL6807219 0.80 SYK (0.47) ATMTACR1NPPAMMECTSL
SCHEMBL10966776 0.79 CTRB1 (0.61) ATMCTRB1CASP1ALDH1A1ALOX15
SCHEMBL28969031 0.78 NPPA (0.47) ATMTACR1NPPAMMEITGA4
SCHEMBL28968928 0.78 NPPA (0.47) ATMTACR1NPPAMMEITGA4
SCHEMBL6261336 0.77 NOTUM (0.49) NPPAMMEALDH1A1FFAR1HDAC3
SCHEMBL30306923 0.77 ATM (0.43) ATMTACR1NPPAMMEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578735-A1 CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS Pfizer Limited (GB) 2005-09-28 EP disclosed
US-20040138274-A1 Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders DACK KEVIN NEIL (GB) 2004-07-15 US disclosed
WO-2004056787-A1 CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS PFIZER LIMITED (GB) 2004-07-08 WO disclosed
WO-2004056787-A1 CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS PFIZER LIMITED (GB) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138274-A1 Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders MME, ECE1, ECE2 ATM 4873/4885CTRB1 173/4885TACR1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.